These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 19124726

  • 1. IL-12-dependent inducible expression of the CD94/NKG2A inhibitory receptor regulates CD94/NKG2C+ NK cell function.
    Sáez-Borderías A, Romo N, Magri G, Gumá M, Angulo A, López-Botet M.
    J Immunol; 2009 Jan 15; 182(2):829-36. PubMed ID: 19124726
    [Abstract] [Full Text] [Related]

  • 2. The CD94/NKG2C killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells.
    Gumá M, Busch LK, Salazar-Fontana LI, Bellosillo B, Morte C, García P, López-Botet M.
    Eur J Immunol; 2005 Jul 15; 35(7):2071-80. PubMed ID: 15940674
    [Abstract] [Full Text] [Related]

  • 3. Expression patterns of lectin-like natural killer receptors, inhibitory CD94/NKG2A, and activating CD94/NKG2C on decidual CD56bright natural killer cells differ from those on peripheral CD56dim natural killer cells.
    Kusumi M, Yamashita T, Fujii T, Nagamatsu T, Kozuma S, Taketani Y.
    J Reprod Immunol; 2006 Jun 15; 70(1-2):33-42. PubMed ID: 16488482
    [Abstract] [Full Text] [Related]

  • 4. Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts.
    Gumá M, Budt M, Sáez A, Brckalo T, Hengel H, Angulo A, López-Botet M.
    Blood; 2006 May 01; 107(9):3624-31. PubMed ID: 16384928
    [Abstract] [Full Text] [Related]

  • 5. The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues.
    Wada H, Matsumoto N, Maenaka K, Suzuki K, Yamamoto K.
    Eur J Immunol; 2004 Jan 01; 34(1):81-90. PubMed ID: 14971033
    [Abstract] [Full Text] [Related]

  • 6. The effect of mifepristone on the peripheral blood natural killer cell's cytotoxicity and expression of CD94/NKG2A and NKG2D during the implantation phase.
    Chen XY, Zhuang YL, Li L, Zhang WW, Huang LL.
    Fertil Steril; 2010 May 15; 93(8):2615-20. PubMed ID: 19880106
    [Abstract] [Full Text] [Related]

  • 7. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Morel E, Escamochero S, Cabañas R, Díaz R, Fiandor A, Bellón T.
    J Allergy Clin Immunol; 2010 Mar 15; 125(3):703-10, 710.e1-710.e8. PubMed ID: 20132973
    [Abstract] [Full Text] [Related]

  • 8. Expression of p58.2 or CD94/NKG2A inhibitory receptors in an NK-like cell line, YTINDY, leads to HLA Class I-mediated inhibition of cytotoxicity in the p58.2- but not the CD94/NKG2A-expressing transfectant.
    Lin Chua H, Brahmi Z.
    Cell Immunol; 2002 Sep 15; 219(1):57-70. PubMed ID: 12473268
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Functional anti-CD94/NKG2A and anti-CD94/NKG2C autoantibodies in patients with systemic lupus erythematosus.
    Hagberg N, Theorell J, Hjorton K, Spee P, Eloranta ML, Bryceson YT, Rönnblom L.
    Arthritis Rheumatol; 2015 Apr 15; 67(4):1000-11. PubMed ID: 25510434
    [Abstract] [Full Text] [Related]

  • 11. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.
    Braud VM, Allan DS, O'Callaghan CA, Söderström K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL, McMichael AJ.
    Nature; 1998 Feb 19; 391(6669):795-9. PubMed ID: 9486650
    [Abstract] [Full Text] [Related]

  • 12. Rat and mouse CD94 associate directly with the activating transmembrane adaptor proteins DAP12 and DAP10 and activate NK cell cytotoxicity.
    Saether PC, Hoelsbrekken SE, Fossum S, Dissen E.
    J Immunol; 2011 Dec 15; 187(12):6365-73. PubMed ID: 22084441
    [Abstract] [Full Text] [Related]

  • 13. CD3+/CD19+-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A.
    Eissens DN, Schaap NP, Preijers FW, Dolstra H, van Cranenbroek B, Schattenberg AV, Joosten I, van der Meer A.
    Leukemia; 2010 Mar 15; 24(3):583-91. PubMed ID: 20033055
    [Abstract] [Full Text] [Related]

  • 14. Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection.
    Jinushi M, Takehara T, Tatsumi T, Kanto T, Miyagi T, Suzuki T, Kanazawa Y, Hiramatsu N, Hayashi N.
    J Immunol; 2004 Nov 15; 173(10):6072-81. PubMed ID: 15528343
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. HLA-G recognition by human natural killer cells. Involvement of CD94 both as inhibitory and as activating receptor complex.
    Pende D, Sivori S, Accame L, Pareti L, Falco M, Geraghty D, Le Bouteiller P, Moretta L, Moretta A.
    Eur J Immunol; 1997 Aug 15; 27(8):1875-80. PubMed ID: 9295021
    [Abstract] [Full Text] [Related]

  • 17. Increased frequency of human leukocyte antigen-E inhibitory receptor CD94/NKG2A-expressing peritoneal natural killer cells in patients with endometriosis.
    Galandrini R, Porpora MG, Stoppacciaro A, Micucci F, Capuano C, Tassi I, Di Felice A, Benedetti-Panici P, Santoni A.
    Fertil Steril; 2008 May 15; 89(5 Suppl):1490-6. PubMed ID: 17706207
    [Abstract] [Full Text] [Related]

  • 18. NK cell CD94/NKG2A inhibitory receptors are internalized and recycle independently of inhibitory signaling processes.
    Borrego F, Kabat J, Sanni TB, Coligan JE.
    J Immunol; 2002 Dec 01; 169(11):6102-11. PubMed ID: 12444112
    [Abstract] [Full Text] [Related]

  • 19. Association of CD94/NKG2A, CD94/NKG2C, and its ligand HLA-E polymorphisms with Behcet's disease.
    Seo J, Park JS, Nam JH, Bang D, Sohn S, Lee ES, Park KS.
    Tissue Antigens; 2007 Oct 01; 70(4):307-13. PubMed ID: 17767552
    [Abstract] [Full Text] [Related]

  • 20. The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression.
    Eugène J, Jouand N, Ducoin K, Dansette D, Oger R, Deleine C, Leveque E, Meurette G, Podevin J, Matysiak T, Bennouna J, Bezieau S, Volteau C, Thomas WEA, Chetritt J, Kerdraon O, Fourquier P, Thibaudeau E, Dumont F, Mosnier JF, Toquet C, Jarry A, Gervois N, Bossard C.
    Mod Pathol; 2020 Mar 01; 33(3):468-482. PubMed ID: 31409873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.